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Sublocalization of the Multiple Endocrine Neoplasia Type 1 Gene

Catharina Larsson,* Gunther Weber,* and Marie Janson'

Tumorigenesis in multiple endocrine neoplasia type 1 (MEN 1 ] involves the unmasking ofa recessive
mutation at the MEN 1 locus which has been mapped to chromosomal region llqll-13. By analyzing
58 DNA markers on a panel of radiation-reduced somatic cell hybrids, the region encompassing the
MEN I gene was divided into nine subregions. Pulsed field gel electrophoresis analysis of markers
within subgroups showed that the recombination rate around the MEN 1 locus is high. Combined
linkage analysis in MEN I families and deletion mapping in MEN I-related tumors suggest the MEN
1 gene is located centromeric to DI1S807 and telomeric to PYGM. (Henry Ford Hosp Med J
1992:40:159-61)

M

ultiple endocrine neoplasia type 1 (MEN 1) is a syndrome
in which neoplastic lesions in the parathyroids, the neuroendocrine pancreas, and the pituitary gland are associated. The
MEN 1 susceptibility locus was mapped to the centromeric part
of the long arm of chromosome 11 by genetic linkage utilizing
restriction fragment length polymorphisms (RFLPs) in three affected families (1). Furthermore, combined family and genotype
analysis have shown that tumorigenesis in MEN 1 involves the
unmasking of a recessive mutation at the MEN 1 locus (1-4).
This is likely accomplished by mitotic recombination or deletion or loss of one chromosome 11 complement (1,3-6). These
findings suggest the possibility of further localization of the
gene by deletion mapping in tumors as well as by identification
of meiotic crossovers in families.
Several strategies are being used to identify the MEN 1 gene
(MENl). A useful start is to identify tianking markers for the
gene. If the putative gene-containing region can be restricted to
less than a few million base pairs, it can be cloned and screened
for expressed sequences. The present linkage map around the
MEN 1 locus includes seven RFLP markers covering approximately 12 cM (7,8), a region too large to be cloned by conventional methods.

Methods
Physical mapping and linkage analysis
The DNA markers available for linkage analysis and physical
mapping include polymorphic and nonpolymorphic plasmid
markers, cosmid clones isolated for locus expansion of the polymorphic plasmid markers, and cosmid clones isolated from somatic cell hybrids containing different parts of human chromosome 11 on a hamster background (9-11).
The DNA markers were localized to different parts of chromosome 11 using a panel of Chinese hamster x human somatic
cell hybrids. J1-C14 carries one intact chromosome 11 while
MC-1, Jl-44, R28-4E, and Jl-11 contain only part of this chromosome (12). The Goss-Harris radiation-reduced hybrids.
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R131-33B1,R184-5D1, R184-4C2, R184-3A1, R184/7C1, and
R184-1A2, were derived from a hybrid cell line containing all of
1 lq and a small part of 1 lp; after gamma-irradiation, the cells
were fused with Chinese hamster cells and selected with a
monoclonal antibody corresponding to a gene encoding a human cell surface antigen (MDUl) mapped to 1 lql3 (13).
Methods for isolation and restriction enzyme cleavage of
DNA, Southem analysis, hybridization to radioactively labeled
probes, and analysis by pulsed field gel electrophoresis (PEGE)
have been described (13,14). Clinical data and scoring have
been published (15,16).

Results and Discussion
Physical mapping
The region of chromosome 11 containing the MEN 1 gene is
defined by seven anchor markers for which the relative order
and map distance have been determined in reference families:
(D11S149-D11 S288)-PGA-PYGM-(D 11S97-D11S146-INT2)1 Iqter. A total of 58 DNA markers have been mapped to this region by hybridization to somatic cell hybrids (11). By analyzing
the same markers on a panel of radiation-reduced somatic cell
hybrids, 53 of the clones were assigned to the Dl 1S149-INT2
region. The radiation-reduced hybrids are designed to carry different parts of chromosomal region l l q l 3 on a hamster background, and from the hybridization pattem the markers were divided into nine groups (11).
This sublocalization of the markers provides a starting point
for more precise mapping with PFGE and linkage analysis
(11,13). Comparison of the physical map (Figure) with the present linkage map indicates considerable variability in the recom-
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Figure—Mapping ofthe MENl region on chromosome 11. An enlarged map ofthe llqll-13 region sho'ws the gene order based on
combined physical mapping and linkage analysis. Anchor markers are those previously mapped in reference families. In each case
the region "excluded" from analysis of recombinational events or deletion mapping is hatched.

bination frequency over the region. In particular, the recombination rate is higher than expected for markers fianking the MEN 1
region. PGA and PYGM are located 3 cM apart (8). They are
physically linked through D11S471 and the distance is less than
875 kb (13). A simdar situation is found on the telomeric side
where D l 1S97, Dl 1S146, and INT2 (which are within 2% meiotic recombinations) are located on the same 1,200 kb Nrul fragment (13).
Linkage analysis
The anchor markers have been used for linkage analysis of
MEN 1 families, to identify meiotic crossovers, and to locate the
disease gene between fianking markers. By using lod score calculations, several recombinants have been detected for INT2
and D11S146 on the telomeric side of MEN l (7,16,17). By the
same method, multiple recombinants have been detected for
D l 1S288 (7,16) and one for PGA (16). These findings indicate
that the MEN 1 gene is fianked centromerically by Dl 1S288D11S149 and telomerically by INT2-D11S146. However,
sublocalization of MENl is most reliable when the crossingover event has been thoroughly outlined in individual cases.
Since such analysis also requires genotyping of the closest rela-
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tives, a detailed analysis is not always possible. The two recombinations outiined in the Figure indicate that the gene is located
between CD20 and Dl 1S807.
Deletion mapping in tumors
MEN 1-associated tumors may result from the unmasking of
a recessive mutation, according to the two-mutation model postulated originally by Knudson (2). Such rearrangements would
then be present in all tumor cells, restricted to a specific chromo.some (18), and serve to eliminate the wild type allele of MEN 1.
In MEN 1 families this has been shown for parathyroid and pancreatic tumors (1,3,4) but not for pituitary or adrenocortical tumors. In the sporadic counterparts of these tumors, allele losses
for chromosome 11 markers have been found in parathyroid but
not in pituitary tumors (3-5). The results from similar analysis of
sporadic pancreatic tumors have been confiicting.
In order to define the minimal region of overlap for deletions
of chromosome 11, a number of MEN 1-associated tumors have
been screened for allele losses (3-6). From these studies, it is evident that mitotic recombinations do occur within the MENl region (4-6). Thus it is difficult to establish an accurate and reliable deletion map. As illustrated in the Figure, for markers
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within the PGA and Dl 1S146 regions, both alleles may be retained while the rest of one chromosome 11 complement is lost.
In one case, combined pedigree and tumor genotype analysis
showed that the lost alleles were always derived from the nonaffected father. In two other parathyroid tumors, the allele losses
were interpreted as simple deletions (Figure).
Taken together, the linkage and deletion mapping analysis
would place MENl telomeric of PYGM and centromeric of
D11S807.
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